Viner KC, Cammack N, Coates JA, Hooker EU, Rouse P, Penn CR, Cameron JM; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 236 (abstract no. PO-A25-0607).
Department of Virology, Glaxo Group Research Limited, Greenford, Middlesex, UK.
OBJECTIVES: We have investigated the inhibition of HIV-1 by combinations of (-)enantiomeric 2'-deoxy-3'-thiacytidine (3TC) with AZT and other inhibitors of HIV. METHODS/RESULTS: The separated enantiomers of the nucleoside analogue 2'-deoxy-3'thiacytidine (BCH189) both inhibit HIV replication in vitro. The (-)enantiomer (3TC) showed potent antiviral activity against a range of HIV-1 and HIV-2 isolates in primary and established CD-4 bearing cells, and had the highest selectivity of the two enantiomers as determined by cytotoxicity experiments in the same cells systems. 3TC and AZT exhibited synergistic inhibition against a range of HIV-1 clinical isolates. 3TC also demonstrated synergy in combination with non-nucleoside inhibitors of reverse transcriptase, and an inhibitor of HIV proteinase against a laboratory isolate of HIV-1. CONCLUSIONS: These results show that in vitro, 3TC acts in synergy with AZT against a range of HIV-1 clinical isolates and with other inhibitors of HIV against a laboratory isolate of HIV-1.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiviral Agents
- HIV
- HIV Infections
- HIV Protease
- HIV Seropositivity
- HIV-1
- HIV-2
- In Vitro
- Lamivudine
- RNA-Directed DNA Polymerase
- Zidovudine
Other ID:
UI: 102203450
From Meeting Abstracts